World’s first stem-cell treatment restores vision for patients with severe corneal damage

A groundbreaking clinical trial in Japan has achieved a significant breakthrough in stem cell therapy, improving vision for three individuals with severe corneal damage due to limbal stem cell deficiency (LSCD). This world-first study represents a major advancement in regenerative medicine.


Two years post-surgery, there were no notable safety concerns, and all three treated corneas appeared significantly clearer. Four participants with LSCD, a disorder that leads to scarring on the cornea, were included in the study. The cornea, often described as the eye's "transparent window," relies on stem cells from the limbus, its “frame,” to maintain clarity. Without these cells, gradual vision deterioration is inevitable.

Why stem cell therapy may transform treatment for corneal diseases?

Patients with LSCD in one eye can sometimes have scar tissue removed and replaced with tissue from their other eye. However, if both eyes are affected, a donor transplant is essential. Globally, only 1 in 70 of the 12.7 million people with cornea-related vision loss can access transplants due to limited donor availability and the risk of rejection.

Induced pluripotent stem cells (iPSCs) offer a promising solution. These versatile cells, which can be reprogrammed from any human cell into an embryonic-like state, were used by scientists at Osaka University Hospital to regenerate damaged corneal cells. For the first time, they achieved this without using the patient's own cells.

In the lab, iPSCs were coaxed into corneal epithelial cell sheets (iCEPS) and transplanted onto the corneas after scar tissue removal. Seven months after surgery, all four patients showed vision improvement, although one experienced some regression after a year, likely due to an immune response.

Future of corneal stem cell therapy

The success of this pilot study has inspired plans for a multicenter clinical trial. The research team noted, “This study provides the first description of iPSC-derived cell constructs transplanted onto patients’ corneas and offers a hopeful new treatment option for LSCD.” Though promising, more research is needed to confirm the long-term safety and efficacy of the procedure. The findings were published in The Lancet.





Also Read | African elephants face shocking 70% population decline due to habitat loss and poaching; study finds